BioSig Technologies amends debenture agreement with Yorkville for up to $100 million

BioSig Technologies, Inc. (NASDAQ:BSGM), which has seen its stock surge over 400% in the past six months according to InvestingPro data, announced Wednesday that it has amended its secured convertible debenture purchase agreement with YA II PN, Ltd. (Yorkville). The amendment revises the structure of the transaction to provide for two secured convertible debentures, each with a principal amount of $25 million, and allows for additional secured convertible debentures totaling up to $50 million to be issued upon mutual agreement by both parties. The company currently operates with a moderate debt level, maintaining a healthy current ratio of 2.37x.

The amendment also modifies certain purchase, closing, and stockholder approval provisions. In addition, the terms have been updated to set the floor price for conversions at 20% of the Nasdaq Official Closing Price immediately prior to the date of entry into the original debenture purchase agreement.

The original agreement between BioSig Technologies and Yorkville was entered into on July 7, 2025, as previously disclosed by the company.

The information in this article is based on a press release statement included in a Form 8-K filing with the Securities and Exchange Commission. InvestingPro analysis shows the company’s overall financial health score as Weak, with 12+ additional key metrics and insights available to subscribers.

In other recent news, BioSig Technologies, Inc. has announced several significant developments. The company secured up to $1.1 billion in growth financing, which includes $100 million in senior secured convertible debentures and a $1 billion equity line of credit. This financing aims to support BioSig’s launch of a gold-backed treasury management strategy, positioning it as one of Nasdaq’s largest public holders of gold bullion. Additionally, BioSig has engaged Compliance Exchange Group to manage the acquisition of a FINRA and SEC registered broker-dealer, focusing on issuing regulated gold-backed digital assets.

BioSig has also made strategic appointments to bolster its subsidiary, Streamex Exchange Corporation. Russell Starr, a seasoned executive with experience in both decentralized and traditional finance, has joined as a Strategic Advisor. Furthermore, Trevor Bacon and Kellan Grenier, co-founders of Parcl, have been appointed as Strategic Advisors to advance BioSig’s commodity market initiatives. In analyst news, Ascendiant Capital upgraded BioSig’s stock, raising the price target from $2.50 to $10, following the successful merger with Streamex Exchange Corp. This merger has also introduced a new leadership team, with Henry McPhie now serving as CEO of the combined entity.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.